Given the abovementioned correlations and the functions of both proteins (NfL and RTN4), a combined analysis of both biomarkers potentially allows for improving the diagnosis of MS, although our study did not confirm this hypothesis. This evidence concerns the gene RTN4 and myeloid sarcoma.